Objective: There is little information on Herpes zoster infection in breast cancer patients as a complication during adjuvant chemotherapy. The aim of this study is to evaluate the incidence of Herpes zoster and simplex infections in this patients setting. Methods: We analyzed 623 early-stage breast cancer patients in our Institute over a period of 7 years (1998–2005). Four-hundred and sixty-onepatients were treated with anthracycline-based chemotherapy, 116 with CMF and 46 with taxane-containing regimens. Results: Twelve (1.9%) developed herpes zoster; 9 patients, receiving anthracycline-based chemotherapy, two taxane-containing regimens, and one CMF regimen. Herpes zoster infection required treatment delay in 6 patients. Adjuvant chemotherapy was delayed for 1 week in 2 patients, while in 4 patients with more severe symptoms chemotherapy was delayed for 2 weeks. One patient, despite i.v. acyclovir, had severe postherpetic motor neuropathy with a permanent ambulation impairment, and chemotherapy was stopped. In our study, herpes zoster occurred in 55/1,000 cases/year. The reported incidence in the general population varies between 2.2 and 4.1 per 1,000 patients/year; therefore, the risk of developing herpes zoster in these patients may be 13- to 25-fold higher compared to the incidence in the general population. In addition, 13 of 623 patients developed herpes simplex. Conclusion: Our findings suggest that adjuvant chemotherapy can facilitate reactivation of herpes infection.

1.
Mazur MH, Dolin R: Herpes zoster at the NIH: a 20-year experience. Am J Med 1978;63:738–744.
2.
Guinee VF, Guido JJ, Pfelzgraf KA, Giacco GG, Legarde C, Durand M, Van der Velden JW, Lowenberg B, Jereb B, Bretsky S: The incidence of herpes zoster in patients with Hodgkin’s disease: an analysis of prognostic factors. Cancer 1985;56:612–618.
3.
Feld R, Evans WK, DeBoer G: Herpes zoster in patients with small cell carcinoma of the lung receiving combined modality treatment. Ann Intern Med 1980;93:282–283.
4.
Feld R, Evans WK, DeBoer G: Herpes zoster in patients with carcinoma of the lung. Am J Med 1982;73:795–801.
5.
Di Luzio Paparatti U, Arpinelli F, Visonà G: Herpes zoster and its complications in Italy: an observational survey. J Infect 1999;38:116–120.
6.
Donahue JG, Choo PW, Manson JE, et al: The incidence of herpes zoster. Arch Intern Med 1995;155:1605–1609.
7.
Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, Van Essen GA: Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2000;19:471–475.
8.
Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA: The incidence of herpes zoster in a United States Administrative Database. J Gen Intern Med 2005;20:748–757.
9.
Klein JL, Hamm C, Dansey RD, Karanes C, Abella E, Cassells L, Peters WP, Baynes RD: High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow. Bone Marrow Transplant 2001;28:1023–1029.
10.
Zambelli A, Montagna D, Da Prada GA, Maccario R, Zibera C, Moretta A, Ponchio L, Lozza L, Baiardi R, Marone P, Della Cuna GR: Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients. Anticancer Res 2002;22:3701–3708.
11.
Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J, Snydman DR: Varicella zoster virus infections following allogenic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000;6:644–649.
12.
Bilgrami S, Chakraborty NG, Rodriguez-Pinero F, Khan AM, Feingold JM, Bona RD, Edwards RL, Dorsky D, Clive J, Mukherji B, Tutschka PJ: Varicella zoster virus infections associated with high-dose chemotherapy and autologous stem cell rescue. Bone Marrow Transplant 1999;23:469–474.
13.
Dunst J, Steil B, Furch S, Fach A, Bormann G, Marsch W: Herpes zoster in breast cancer patients after radiotherapy.Strahlenther Onkol 2000;176:513–516.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.